Cover Image
市場調查報告書

全球特發性肺纖維化治療藥市場預測 (∼2027年):抗纖維劑,蛋白酪氨酸激酶抑制劑,抗發炎劑,免疫抑制劑,其他的單株抗體,創新藥,未認證藥

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs

出版商 Visiongain Ltd 商品編碼 602845
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球特發性肺纖維化治療藥市場預測 (∼2027年):抗纖維劑,蛋白酪氨酸激酶抑制劑,抗發炎劑,免疫抑制劑,其他的單株抗體,創新藥,未認證藥 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs
出版日期: 2017年12月14日 內容資訊: 英文 162 Pages
簡介

全球特發性肺纖維化治療藥市場今後將以16.7%的年複合成長率擴大。抗纖維劑佔最大佔有率 (52%) ,其次是蛋白酪氨酸激酶抑制劑。

本報告提供全球特發性肺纖維化治療藥市場相關調查,市場概要和各市場區隔,各地區趨勢,及加入此市場的主要企業的簡介等彙整資料。

第1章 本報告概要

第2章 特發性肺纖維化的簡介

第3章 全球特發性肺纖維化治療藥的簡介

  • 市場結構
  • 市場定義和範圍
  • 各作用機制分類
  • 創新或未認證藥分類

第4章 全球市場 (2017∼2027年)

  • 全球市場:2016年
  • 全球市場預測 (2017∼2027年)
  • 各作用機制市場區隔
  • 創新或未認證藥市場
  • 推動市場的要素,阻礙要素,趨勢

第5章 主力藥物

  • 銷售額 (實際成果與預測) 概要
  • 未認證藥

第6章 主要國家市場

  • 各地區明細
  • 各地區市場預測
  • 美國市場
  • 市場歐洲5個國家
  • 日本市場
  • 其他各國市場

第7章 研究開發

  • 開發平台藥物的新作用機制
  • 關注的化合物
  • 有前途的化合物

第8章 藥價和償付概要

  • Ofev
  • Esbriet

第9章 定性分析

  • SWOT分析

第10章 主要企業

  • Roche
  • Boehringer Ingelheim

第11章 結論

附錄

目錄
Product Code: PHA0267

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2016, the anti-fibrotics held the largest market share (52%) followed by the tyrosine kinase inhibitors.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 57 tables and 97 figures- all unavailable elsewhere.

The 162-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2027
  • This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
    • Antifibrotics
    • Tyrosine Kinase Inhibitors
    • Anti-inflammatory Drugs
    • Immunosuppressants
    • Other MoA
  • This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
    • Innovator Drugs
    • Off-label Drugs
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • Japan
    • EU5: Germany, France, the UK, Italy, Spain
    • Rest of Europe
    • Rest of World
  • This report provides individual revenue forecasts to 2027 for these marketed drugs:
    • Esbriet
    • Ofev
  • Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
    • Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets (Historical 2010-2015, 2016 data, Forecast 2017-2027)
    • Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
    • Epidemiology of Idiopathic Pulmonary Fibrosis by gender
    • Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
    • Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
    • A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market
  • Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
    • Actelion
    • Afferent Pharmaceuticals
    • Asahi Kasei Pharma
    • Bellerophon Therapeutics
    • Biogen
    • Boehringer Ingelheim
    • FibroGen
    • Galapagos
    • Galecto Biotech
    • Genentech
    • Global Blood Therapeutics
    • GSK
    • Kadmon Pharmaceuticals
    • LTT Bio-Pharma
    • MediciNova
    • Merck
    • Moerae
    • Pacific Therapeutics
    • Promedior
    • ProMetic Life Sciences
    • Roche
    • Sanofi
    • Teva
    • Zai Lab

Visiongain's study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report Include:
  • 1.4. Who is This Report For?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to the Idiopathic Pulmonary Fibrosis (IPF)

  • 2.1. What is IPF?
  • 2.2. Aetiology - Causes and Risk Factors
  • 2.3. Symptoms
  • 2.4. Stages of IPF
  • 2.5. Diagnosis
    • 2.5.1. Diagnostic Tests
    • 2.5.2. Pulmonary Function Testing/Lung Function Testing
    • 2.5.3. Oximetry
    • 2.5.4. Lung Biopsy
    • 2.5.5. Chest X-ray
    • 2.5.6. Computerized Tomography (CT)
    • 2.5.7. Echocardiogram
  • 2.6. Epidemiology
    • 2.6.1. Methodology
    • 2.6.2. Epidemiology by Country
    • 2.6.3. Epidemiology by Disease Severity
    • 2.6.4. Epidemiology by Gender
    • 2.6.5. Historical Prevalence in Major Markets
    • 2.6.6. Forecast of IPF in Major Markets: 2016-2027
      • 2.6.6.1. The US
      • 2.6.6.2. France
      • 2.6.6.3. Germany
      • 2.6.6.4. The United Kingdom
      • 2.6.6.5. Italy
      • 2.6.6.6. Spain
      • 2.6.6.7. Japan
  • 2.7. Humanistic and Economic Burden
    • 2.7.1. Co-morbidities
    • 2.7.2. Mortality
    • 2.7.3. Healthcare Utilization & Economic Burden
  • 2.8. Prevention and Treatment
    • 2.8.1. Guidelines
    • 2.8.2. Non-pharmacologic Management
      • 2.8.2.1. Quit Smoking
      • 2.8.2.2. Oxygen therapy
      • 2.8.2.3. Pulmonary Rehabilitation
      • 2.8.2.4. Vaccination
      • 2.8.2.5. Maintain Healthy Weight
      • 2.8.2.6. Lung Transplantation
    • 2.8.3. Pharmacologic Treatments

3. Introduction to the Global Anti- Anti-Idiopathic Pulmonary Fibrosis Drugs Market

  • 3.1. Market Structure
  • 3.2. Market Definition and Scope
  • 3.3. Classification by Mechanism of Action
    • 3.3.1. Anti-fibrotics
    • 3.3.2. Tyrosine Kinase Inhibitors
    • 3.3.3. Anti-inflammatory Drugs
    • 3.3.4. Immunosuppressants
    • 3.3.5. Other Mechanisms
  • 3.4. Classification by Innovator or Off-label Drugs
    • 3.4.1. Innovator Drugs
    • 3.4.2. Off-label Drugs

4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2017-2027

  • 4.1. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2016
  • 4.2. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2017-2027
  • 4.3. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action
  • 4.4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Forecast 2017-2027
    • 4.4.1. Global Anti-fibrotics Drugs Market Forecast, 2016-2027
    • 4.4.2Global Tyrosine Kinase Inhibitors Drugs Market Forecast, 2016-2027
    • 4.4.3. Global Anti-inflammatory Drugs Market Forecast, 2016-2027
    • 4.4.4. Global Immunosuppressants Drugs Market Forecast, 2016-2027
    • 4.4.5. Other MoA Drugs Market Forecast, 2016-2027
    • 4.4.6. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Share Forecast 2017-2027
  • 4.5. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs, 2016
    • 4.5.1. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label drugs: Forecast 2017-2027
  • 4.5.1.1. Global Innovator Drugs Market Forecast, 2016-2027
  • 4.5.1.2. Global Off-label Drugs Market Forecast, 2016-2027
    • 4.5.2. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label Drugs: Share Forecast 2016-2027
  • 4.6. Overall Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Drivers, Restraints and Trends

5. Leading Anti-Idiopathic Pulmonary Fibrosis Drugs

  • 5.1. Snapshot of Anti-Idiopathic Pulmonary Fibrosis Drugs' 2016 Sales, Historical Sales, & Forecast 2017-2027
    • 5.1.1. Esbriet
      • 5.1.1.1. Esbriet: Drug Profile
      • 5.1.1.2. Esbriet: Historical Sales
      • 5.1.1.3. Esbriet Sales Forecast 2017-2027
      • 5.1.1.4. Esbriet Sales by Geography, 2016
    • 5.1.2. Ofev
      • 5.1.2.1. Ofev: Drug Profile
      • 5.1.2.2. Ofev: Historical Sales
      • 5.1.2.3. Ofev: Forecast 2017-2027
      • 5.1.2.4. Ofev: Sales by Geography, 2016
  • 5.2. Off-label Drugs

6. Leading National Markets Forecast 2017-2027

  • 6.1. Geographical Breakdown of Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • 6.2. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region, 2017-2027
  • 6.3. US Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
    • 6.3.1. US Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
  • 6.4. EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
    • 6.4.1. EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
      • 6.4.1.1. Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
      • 6.4.1.2. The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
      • 6.4.1.3. France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
      • 6.4.1.4. Spain Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
      • 6.4.1.5. Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
  • 6.5. Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
  • 6.6. RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027

7. Research and Development for Treating IPF

  • 7.1. Novel Mechanism of Action of Pipeline Drugs
  • 7.2. Active Pipeline Molecules
  • 7.3. Promising Potential Pipeline Molecules
    • 7.3.1. Phase III Molecules
      • 7.3.1.1. Recomodulin (ART-123)
    • 7.3.2. Phase II Molecule
      • 7.3.2.1. Pamrevlumab (FG-3019)
      • 7.3.2.2. PRM-151
      • 7.3.2.3. Erivedge (Vismodegib)
      • 7.3.2.4. Opsumit (Macitentan)
      • 7.3.2.5. INOpulse
      • 7.3.2.6. GBT-440
      • 7.3.2.7. Tipelukast (MN-001)
      • 7.3.2.8. TD-139
      • 7.3.2.9. BG00011 (STX-100)
      • 7.3.2.10. LT-1001 & LT-1002
      • 7.3.2.11. KD-025 (SLx-2119)
      • 7.3.2.12. SAR 156597
      • 7.3.2.13. PBI4050
      • 7.3.2.14. MK-7264(AF 219)
      • 7.3.2.15. Lebrikizumab
      • 7.3.2.16. GLPG-1690
    • 7.3.3. Phase I trial
      • 7.3.3.1. PXS 4728A
      • 7.3.3.2. PTL 202
      • 7.3.3.3. GSK3008348
      • 7.3.3.4. Omipalisib (GSK-2126458)
      • 7.3.3.5. MMI-0100
      • 7.3.3.6. Deupirfenidone(SD 560)
      • 7.3.3.7. ZL 2012

8. Pricing and Reimbursement Overview

  • 8.1. Ofev
    • 8.1.1. NICE (UK)
    • 8.1.2. SMC (Scotland)
    • 8.1.3. PBAC (Australia)
    • 8.1.4. CADTH (Canada)
    • 8.1.5. G-BA (Germany)
    • 8.1.6. HAS (France)
    • 8.1.7. Overall HTA Challenges
  • 8.2. Esbriet
    • 8.2.1. NICE (UK)
    • 8.2.2. SMC (Scotland)
    • 8.2.3. G-BA (Germany)
    • 8.2.4. HAS (France)
    • 8.2.5. CADTH (Canada)

9. Qualitative Analysis of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market

  • 9.1. SWOT Analysis, 2016

10. Leading Companies in the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016

  • 10.1. Roche
  • 10.2. Boehringer Ingelheim

11. Conclusions

Appendices

  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 1.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation Overview
  • Figure 2.1: Types of Idiopathic Interstitial Pneumonias
  • Figure 2.2: Pathogenesis of Idiopathic Pulmonary Fibrosis
  • Figure 2.3: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016(absolute cases)
  • Figure 2.4: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016(%)
  • Figure 2.5: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016(%)
  • Figure 2.6: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Gender in G7 Markets, ages 40+, 2016(%)
  • Figure 2.7: Historical Prevalence of IPF in G7 Markets, absolute cases; 2010-2015
  • Figure 2.8: Historical Prevalence of IPF in G7 Markets, CAGR, 2010-2015
  • Figure 2.9: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the US, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.10: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.11: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.12: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the UK, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.13: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.14: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.15: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR(%), 2016-2027
  • Figure 2.16: Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines
  • Figure 3.1: Anti-Idiopathic Pulmonary Fibrosis Drugs Classification by Mechanism of Action, 2017
  • Figure 3.2: Inflammatory Pathway in IPF
  • Figure 4.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue($m), AGR(%)
  • Figure 4.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action 2016, Revenue($m)
  • Figure 4.3: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share(%), 2016
  • Figure 4.4: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016-2027: Revenue($m), AGR(%)
  • Figure 4.5: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016 and 2027: Revenue($m), CAGR(%), 2016 and 2027
  • Figure 4.6: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR(%), 2016-2027
  • Figure 4.7: Global Antifibrotic Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.8: Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.9: Global Anti-inflammatory Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.10: Global Immunosuppressants Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.11: Global Other MoA Drugs Market: Revenue($m), AGR(%), 2016-2027 Forecast by Mechanism of Action: Market Share(%), 2016-2027
  • Figure 4.12: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share(%), 2016-2027
  • Figure 4.13: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share Forecast(%), 2017
  • Figure 4.14: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share(%), 2027
  • Figure 4.15: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Revenue($m), 2016
  • Figure 4.16: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Market Share(%), 2016
  • Figure 4.17: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label drugs: Revenue($m), Global AGR(%), 2016-2027
  • Figure 4.18: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue 2016 and 2027($m), CAGR 2016-2027(%)
  • Figure 4.19: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: AGR(%), 2016-2027
  • Figure 4.20: Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.21: Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 4.22: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label Drugs: Market Share(%), 2016-2027
  • Figure 4.23: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share(%), 2017
  • Figure 4.24: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share(%), 2027
  • Figure 4.25: Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • Figure 4.26: Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • Figure 5.1: Leading Anti-Idiopathic Pulmonary Fibrosis Drugs Sales, Revenue($m), 2016
  • Figure 5.2: Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Market Share(%), 2016
  • Figure 5.3: Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Market Share(%), 2027
  • Figure 5.4: Global Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Ofev and Esbriet, Revenue($m), 2016-2027
  • Figure 5.5: Leading Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales, Revenue($m), 2011-2016
  • Figure 5.6: Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales Trend, Revenue($m), 2011-2016
  • Figure 5.7: Esbriet Global Sales: Revenue($million), 2011-2016
  • Figure 5.8: Esbriet Sales Forecast 2016-2027: Revenue($million), AGR(%)
  • Figure 5.9: Esbriet Sales by Geography: Revenue($m), 2016
  • Figure 5.10: Esbriet Sales by Geography: Market Share(%), 2016
  • Figure 5.11: Ofev Global Sales: Revenue($m), 2014-2016
  • Figure 5.12: Ofev Sales Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 5.13: Ofev Sales by Geography: Revenue($m), 2016
  • Figure 5.14: Ofev Sales by Geography: Market Share(%), 2016
  • Figure 5.15: Global Anti-Idiopathic Pulmonary Fibrosis Off-label drugs Market: Market Share by Individual Compound(%), 2016
  • Figure 6.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Region/Country
  • Figure 6.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue($m), 2016
  • Figure 6.3: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share 2016(%)
  • Figure 6.4: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue($m), AGR(%), 2016-2027
  • Figure 6.5: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region 2016, 2022, 2027: Revenue($m), CAGR 2016-2027(%)
  • Figure 6.6: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR(%), 2016-2027
  • Figure 6.7: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share(%), 2016-2027
  • Figure 6.8: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2017(%)
  • Figure 6.9: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2022(%)
  • Figure 6.10: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2027(%)
  • Figure 6.11: Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the US: 2016 Revenue($m), Market Share %
  • Figure 6.12: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the US 2016-2027: Revenue($m), AGR(%)
  • Figure 6.13: Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5: Global Market Share(%), 2016
  • Figure 6.14: Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5 Countries: Market Share(%), 2016
  • Figure 6.15: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries: Revenue($m), EU5 AGR(%), 2016-2027
  • Figure 6.16: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries 2016 and 2027: Revenue($m), CAGR 2016-2027(%)
  • Figure 6.17: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share(%), 2016-2027
  • Figure 6.18: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Global Market Share(%), 2027
  • Figure 6.19: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share(%), 2017
  • Figure 6.20: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share(%), 2027
  • Figure 6.21: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR(%), 2016-2027
  • Figure 6.22: Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 6.23: The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 6.24: France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 6.25: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue($m), AGR(%), 2016-2027
  • Figure 6.26: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Italy: Revenue($m), AGR(%), 2016-2027
  • Figure 6.27: Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), 2016-2027
  • Figure 6.28: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in RoW: Revenue($m), AGR(%),2016-2027
  • Figure 7.1: Anti-Idiopathic Pulmonary Fibrosis Clinical Pipeline Segmentation by Phase, 2016
  • Figure 7.2: Key Molecular Targets of Idiopathic Pulmonary Fibrosis
  • Figure 7.3: Recomodulin - Mechanism of Action
  • Figure 9.1: SWOT Analysis of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • Figure 10.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue($m), 2016
  • Figure 10.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share(%), 2016
  • Figure 10.3: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue($m) 2016
  • Figure 11.1: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016(%)
  • Figure 11.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue($m), AGR(%)

List of Tables

  • Table 2.1: GAP Index for IPF
  • Table 2.2: GAP Staging for IPF
  • Table 2.3: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016(absolute cases)
  • Table 2.4: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016(absolute cases)
  • Table 2.5: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016-2027(absolute cases): AGR(%), CAGR(%)
  • Table 2.6: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the US, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.7: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.8: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.9: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the UK, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.10: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.11: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 2.12: Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR(%), CAGR(%), 2016-2027
  • Table 3.1: Anti-fibrotic molecular targets and pharmacologic agents
  • Table 3.2: Mechanism of Action of Innovator Drugs for the treatment of IPF
  • Table 4.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Markets by Segmentation: Revenue($m), and Market Share(%), 2016
  • Table 4.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue($m), AGR(%), CAGR(%)
  • Table 4.3: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016-2027: Revenue($m), AGR(%), CAGR(%)
  • Table 4.4: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR(%), 2016-2027
  • Table 4.5: Global Antifibrotic Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.6: Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.7: Global Anti-inflammatory Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.8: Global Immunosuppressants Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.9: Global Other MoA Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.10: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share(%), 2016-2027
  • Table 4.11: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.12: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: AGR(%), 2016-2027
  • Table 4.13: Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.14: Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 4.15: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label Drugs: Market Share(%), 2016-2027
  • Table 5.1: Branded Anti-Idiopathic Pulmonary Fibrosis Drugs
  • Table 5.2: Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Revenue($m), Market Share(%), 2016
  • Table 5.3: Esbriet: Drug Profile
  • Table 5.4: Esbriet Sales Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 5.5: Ofev: Drug Profile
  • Table 5.6: Ofev Sales Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue($m), and Market Share(%), 2016
  • Table 6.2: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.3: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR(%), 2016-2027
  • Table 6.4: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share(%), 2016-2027
  • Table 6.5: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the US 2016-2027: Revenue($m), AGR(%), CAGR(%)
  • Table 6.6: Anti-Idiopathic Pulmonary Fibrosis Drugs in the EU5 region: Revenue($m), Global Market Share(%), EU5 Market Share(%), 2016
  • Table 6.7: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in EU5 Region: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.8: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU Region: Market Share(%), 2016-2027
  • Table 6.9: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR(%), 2016-2027
  • Table 6.10: Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.11: The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.12: France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.13: Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.14: Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.15: Japan nti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 6.16: RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue($m), AGR(%), CAGR(%), 2016-2027
  • Table 7.1: Active Pipeline Molecules under Development for Treating IPF
  • Table 7.2: Pamrevlumab - Completed and Ongoing Clinical Trials
  • Table 8.1: Ofev: HTA Agencies' Decision Outcomes
  • Table 8.2: Esbriet: HTA Agencies' Decision Outcomes
  • Table 10.1: Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share(%), 2016

Companies Listed

  • Actelion
  • Afferent Pharmaceuticals
  • American Thoracic Society (ATS)
  • Asahi Kasei Pharma
  • Auspex Pharmaceuticals
  • Bellerophon Therapeutics
  • Biogen Idec.
  • BMS
  • Boehringer Ingelheim
  • Canadian Agency for Drugs and Technologies in Health (CADTH) (Canada)
  • Curis
  • European Commission
  • European Respiratory Society (ERS)
  • FDA
  • FibroGen
  • Galapagos
  • Galecto
  • Genentech
  • Global Blood Therapeutics
  • Haute Autorité de Santé (HAS) (France)
  • Ikaria
  • Ildong Pharmaceutical Co., Ltd.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (Germany)
  • IntelGenX
  • InterMune
  • Janssen
  • Japanese Respiratory Society (JRS)
  • Kadmon Corporation
  • Kadmon Holdings
  • Kedem Pharmaceuticals
  • Kyorin
  • Latin American Thoracic Association (ALAT)
  • LTT Bio-Pharma
  • MediciNova
  • Merck
  • MicroDose Therapeutx
  • Moerae Matrix
  • Nano Terra
  • National Institute for Health and Care Excellence (NICE)
  • Nippon Shinyaku
  • Pacific Therapeutics
  • Pharmaceutical Benefits Advisory Committee (PBAC) (Australia)
  • Pharmaxis
  • Promedior
  • ProMetic Life Sciences
  • Quintiles
  • Roche
  • Sanofi
  • Scottish Medicines Consortium (SMC) (Scotland)
  • Shionogi & Co., Ltd
  • Stromedix Inc.
  • Synairgen
  • Teva
  • Zai Lab
Back to Top